Diana Carolina Andrade

Diana Carolina Andrade

Auto-generated profile, based on publicly available information

Diana Carolina Andrade

Medical Science Liaison, AbbVie (Memorial Hospital West), Pompano Beach Florida

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in IDCases
Verified
Journal Article
Open access
NINicole M. Ianniello
Nicole M. Ianniello
DADiana C. Andrade
Diana C. Andrade
SIStipe Ivancic
Stipe Ivancic
PEPaula A. Eckardt
Paula A. Eckardt
JRJuan C. Lemos Ramirez
Juan C. Lemos Ramirez
Micrococcus species are typically considered contaminants from skin and mucous membranes. However, especially in severely immunocompromised patients, a blood culture with Micrococcus could be the cause of a significant infection. We report a 65-year-old female with non-Hodgkin's lymphoma who developed native valve infective endocarditis due to Micrococcus luteus. There is no defined therapeutic regimen for infective endocarditis due to Micrococcus luteus; however, our patient was successfully treated for six weeks with vancomycin and rifampin. To our knowledge, there is only one other case report of native valve endocarditis due to Micrococcus luteus.

19 November 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JGJulia Gonzalez
Julia Gonzalez
DADiana Carolina Andrade
Diana Carolina Andrade
JNJianli Niu
Jianli Niu
Background: Acute bacterial skin and skin structure infections (ABSSSIs) are common infectious diseases that cause a significant economic burden on the healthcare system. This study aimed to compare the cost-effectiveness of dalbavancin vs standard of care (SoC) in the treatment of ABSSSI in a community-based healthcare system. Methods: This was a retrospective study of adult patients with ABSSSI treated with dalbavancin or SoC during a 27-month period. Patients were matched based on age and body mass index. The primary outcome was average net cost of care to the healthcare system per patient, calculated as the difference between reimbursement payments and the total cost to provide care to the patient. The secondary outcome was proportion of cases successfully treated, defined as no ABSSSI-related readmission within 30 days after the initiation of treatment. Results: Of the 418 matched patients, 209 received SoC and 209 received dalbavancin. The average total cost of care per patient was greater with dalbavancin vs SoC ($4770 vs $2709, P < .0001). The average reimbursement per patient was $3084 with dalbavancin vs $2633 SoC (P = .527). The net cost, calculated as revenue minus total cost, was $1685 with dalbavancin vs $75 with SoC (P = .013). The overall treatment success rate was 74% with dalbavancin vs 85% with SoC (P = .004). Conclusions: Dalbavancin was more costly than SoC for the treatment of ABSSSI, with a higher 30-day readmission rate. Dalbavancin does not offer an economic or efficacy advantage.

11 June 2020 in Pharmacy
Verified
Journal Article
Open access
PDF file
VHVanessa Huffman
Vanessa Huffman
DADiana Carolina Andrade
Diana Carolina Andrade
JHJared Ham
Jared Ham
KBKyle Brown
Kyle Brown
LMLeonid Melnitsky
Leonid Melnitsky
JPJayesh Parmar
Jayesh Parmar
Methicillin-resistant Staphylococcus aureus (MRSA) polymerase-chain-reaction nasal swabs (PCRNS) are a rapid diagnostic tool with a high negative predictive value. A PCRNS plus education “bundle” was implemented to inform clinicians on the utility of PCRNS for anti-MRSA therapy de-escalation in respiratory tract infections (RTI). The study included patients started on vancomycin with a PCRNS order three months before and after bundle implementation. The primary objective was the difference in duration of anti-MRSA therapy (DOT) for RTI. Secondary objectives included hospital length of stay (LOS), anti-MRSA therapy reinitiation, 30-day readmission, in-hospital mortality, and cost. We analyzed 62 of 110 patients screened, 20 in the preintervention and 42 in the postintervention arms. Mean DOT decreased after bundle implementation by 30.3 h (p = 0.039); mean DOT for patients with a negative PCRNS decreased by 39.7 h (p = 0.014). Median cost was lower after intervention [USD$51.69 versus USD$75.30 (p < 0.01)]. No significant difference in LOS, mortality, or readmission existed. The bundle implementation decreased vancomycin therapy and cost without negatively impacting patient outcomes.

21 September 2020 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
DADiana C Andrade
Diana C Andrade
MFMariya Fatakhova
Mariya Fatakhova
SFShahnaz Fatteh
Shahnaz Fatteh
HRHeysu Rubio-Gomez
Heysu Rubio-Gomez
Introduction: The incidence of acyclovir-induced hypersensitivity is rare. To our knowledge, there are four published case reports of oral acyclovir desensitization in adults. Evidence-based guidelines prompt the use of acyclovir for herpes simplex virus (HSV) prophylaxis and treatment. Literature on the cross-reactivity of structurally similar antiviral agents is conflicting, presenting a clinical challenge when choosing an alternative agent. This is a case of successful acyclovir desensitization in an allogeneic stem cell transplant patient. Case Report: A 69-year-old female patient, diagnosed with myelodysplastic/myeloproliferative neoplasm, presented to the hospital for donor mismatch allogeneic bone marrow transplant. The patient reported acyclovir-induced angioedema while receiving treatment for non-complicated herpes zoster (shingles) infection. Management & Outcome: After the acyclovir oral desensitization was conducted in an ICU setting with 1:1 patient-nurse ratio, the patient was successfully started on acyclovir therapy, 800mg by mouth twice daily for HSV prophylaxis with no further complications. Discussion: Oral acyclovir desensitization can provide an option for HSV therapy in patients reporting severe allergy.

1 January 2022 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
GBGeorandy B. Bernard
Georandy B. Bernard
SMSheila Montalvo
Sheila Montalvo
SIStipe Ivancic
Stipe Ivancic
PEPaula Eckardt
Paula Eckardt
KPKenneth Kehn-Yao Poon
Kenneth Kehn-Yao Poon
DADiana C. Andrade
Diana C. Andrade

14 June 2022 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
GBGeorandy B. Bernard
Georandy B. Bernard
SMSheila Montalvo
Sheila Montalvo
SIStipe Ivancic
Stipe Ivancic
PEPaula Eckardt
Paula Eckardt
KPKenneth Kehn-Yao Poon
Kenneth Kehn-Yao Poon
DADiana C. Andrade
Diana C. Andrade